- Home
- NUVL vs BXSL Comparison
NUVL vs BXSL Comparison
Compare NUVL & BXSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- BXSL
- Stock Information
- Founded
- NUVL 2017
- BXSL 2018
- Country
- NUVL United States
- BXSL United States
- Employees
- NUVL N/A
- BXSL N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- BXSL Trusts Except Educational Religious and Charitable
- Sector
- NUVL Health Care
- BXSL Finance
- Exchange
- NUVL Nasdaq
- BXSL Nasdaq
- Market Cap
- NUVL 5.5B
- BXSL 6.0B
- IPO Year
- NUVL 2021
- BXSL N/A
- Fundamental
- Price
- NUVL $79.49
- BXSL $34.27
- Analyst Decision
- NUVL Strong Buy
- BXSL Strong Buy
- Analyst Count
- NUVL 11
- BXSL 9
- Target Price
- NUVL $112.36
- BXSL $28.25
- AVG Volume (30 Days)
- NUVL 420.4K
- BXSL 981.9K
- Earning Date
- NUVL 03-04-2025
- BXSL 11-08-2023
- Dividend Yield
- NUVL N/A
- BXSL 9.77%
- EPS Growth
- NUVL N/A
- BXSL N/A
- EPS
- NUVL N/A
- BXSL N/A
- Revenue
- NUVL N/A
- BXSL $491,357,000.00
- Revenue This Year
- NUVL N/A
- BXSL $195.77
- Revenue Next Year
- NUVL N/A
- BXSL $1.83
- P/E Ratio
- NUVL N/A
- BXSL N/A
- Revenue Growth
- NUVL N/A
- BXSL 27.36
- 52 Week Low
- NUVL $61.80
- BXSL $23.82
- 52 Week High
- NUVL $113.51
- BXSL $31.64
- Technical
- Relative Strength Index (RSI)
- NUVL 43.83
- BXSL 67.08
- Support Level
- NUVL $77.84
- BXSL $33.97
- Resistance Level
- NUVL $85.21
- BXSL $34.64
- Average True Range (ATR)
- NUVL 3.78
- BXSL 0.57
- MACD
- NUVL -0.46
- BXSL 0.07
- Stochastic Oscillator
- NUVL 12.08
- BXSL 79.05
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About BXSL Blackstone Secured Lending Fund of Beneficial Interest
Blackstone Secured Lending Fund is a non-diversified, closed-end management investment company. The investment objectives of the company are to generate current income and, to a lesser extent, long-term capital appreciation. The company seeks to achieve its investment objectives through originated loans and other securities, including syndicated loans, of private U.S. companies, typically in the form of first lien senior secured and unitranche loans, and unsecured and subordinated loans and other debt and equity securities.